Be in the know. 10 key reads for Monday…

  1. Wells Fargo upgraded to Outperform from Peer Perform at Wolfe Research (TheFly)
  2. Oracle Wins TikTok Bid, Beating Out Microsoft and Walmart (Barron’s)
  3. Boeing execs defend safety decisions on 737 MAX development (FoxBusiness)
  4. Investors in Japan should get set for a ‘Suga high’ (Financial Times)
  5. Gilead Sciences Agrees $21 Billion Takeover Of Cancer Drug Specialist Immunomedics (TheStreet)
  6. Why Fed Officials Are Begging for More Stimulus From Lawmakers (Wall Street Journal)
  7. Stocks Rallied, and Many Missed Out (Wall Street Journal)
  8. Here’s why markets shouldn’t overlook the Fed meeting next Wednesday (MarketWatch)
  9. Pfizer CEO: Coronavirus vaccine could be distributed in U.S. by end of year (MarketWatch)
  10. Nvidia Is Buying Arm Holdings in Largest Ever Chip Deal (Barron’s)

Be in the know. 14 Key reads for Sunday…

  1. Warren Buffett’s $570 million bet on Snowflake shows he completely trusts his deputies, investor Jake Taylor says (Business Insider)
  2. Oxford and AstraZeneca resume coronavirus vaccine trial (Financial Times)
  3. We Buy A Junk Bond (NPR Planet Money)
  4. 10 Scientific Laws and Theories You Really Should Know (How Stuff Works)
  5. A Primer on Algorithms and Bias (Farnam Street)
  6. The Fed Will Trigger Hot-Running Inflation, Druckenmiller Warns (CIO)
  7. Where to Find Bargains in Oil Stocks Now (Barron’s)
  8. After Abe, more Abenomics — for better or worse (Pensions&Investments)
  9. Goldman’s 10 Reasons That the Bull Market Will Resume (CIO)
  10. Pfizer proposes expansion of late-stage coronavirus vaccine trial (CNBC)
  11. Gilead is getting closer to a deal to buy Immunomedics for more than $20 billion (CNBC)
  12. Japan’s Suga says no limit to bonds government can issue (Reuters)
  13. Southern California Research Institute Receives FDA Greenlight for Ivermectin Clinical Trial (TrialSiteNews)
  14. Small Caps Emerge Relatively Unscathed in Megatech Bludgeoning (Bloomberg)